167 related articles for article (PubMed ID: 29269300)
1. MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.
Ping W; Gao Y; Fan X; Li W; Deng Y; Fu X
Biochem Biophys Res Commun; 2018 Jan; 495(4):2482-2489. PubMed ID: 29269300
[TBL] [Abstract][Full Text] [Related]
2. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
3. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
4. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.
Shen H; Zhu F; Liu J; Xu T; Pei D; Wang R; Qian Y; Li Q; Wang L; Shi Z; Zheng J; Chen Q; Jiang B; Shu Y
PLoS One; 2014; 9(7):e103305. PubMed ID: 25058005
[TBL] [Abstract][Full Text] [Related]
5. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
6. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
7. miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Nishijima N; Seike M; Soeno C; Chiba M; Miyanaga A; Noro R; Sugano T; Matsumoto M; Kubota K; Gemma A
Int J Oncol; 2016 Mar; 48(3):937-44. PubMed ID: 26783187
[TBL] [Abstract][Full Text] [Related]
8. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
9. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.
Jin S; He J; Li J; Guo R; Shu Y; Liu P
Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075
[TBL] [Abstract][Full Text] [Related]
10. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
11. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
[TBL] [Abstract][Full Text] [Related]
12. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.
Zhong M; Ma X; Sun C; Chen L
Chem Biol Interact; 2010 Mar; 184(3):431-8. PubMed ID: 20097187
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
Wang N; Zhang T
Oncol Res; 2018 Aug; 26(7):1005-1014. PubMed ID: 29295721
[TBL] [Abstract][Full Text] [Related]
15. Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498.
Lu M; Liu B; Xiong H; Wu F; Hu C; Liu P
J Cell Mol Med; 2019 Apr; 23(4):2431-2441. PubMed ID: 30701693
[TBL] [Abstract][Full Text] [Related]
16. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
18. Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation.
Wang S; Su X; Bai H; Zhao J; Duan J; An T; Zhuo M; Wang Z; Wu M; Li Z; Zhu J; Wang J
J Hematol Oncol; 2015 Nov; 8():127. PubMed ID: 26563758
[TBL] [Abstract][Full Text] [Related]
19. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Hu FY; Cao XN; Xu QZ; Deng Y; Lai SY; Ma J; Hu JB
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):839-845. PubMed ID: 27924500
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
